演講嘉賓

Piu Chan, MD, PhD, Professor of Neurology and Geriatrics, is the Chair of the faculty of Geriatrics and the Director of Clinical and Research Center for Parkinson’s Disease (PD), Capital Medical University. He serves as the director of National Clinical Research Center for Geriatric Disorders, and Parkinson’s Disease Center of Beijing Institutes of Brain Disorders, Xuanwu Hospital. He is also the council member of the International Association of Gerontology and Geriatrics (IAGG), past Secretary of the IAGG Asia-Oceania Region, and the deputy President of the Chinese Association of Gerontology and Geriatrics (CAGG). He has participated in the development of WHO ICOPE project and its implementation in China. He Dr. Chan has participated in drafting the Clinical Diagnostic Criteria for PD and for Prodromal PD of MDS. He published more than 400 peer reviewed SCI articles with a Google H-index of 92. Dr Chan has been the Principal Investigator for more than 10 international and domestic multi-center clinical register trials, served as consultant for NMPA-CDE. He is currently served as associate editor of Neuropharmacology and Therapy.

Xuemei Chen received a B.S. degree from Peking University, China in 1988 and a doctorate from Cornell University, USA in 1995. After postdoctoral training at California Institute of Technology, she started her assistant professor position in 1999 at the Waksman Institute at Rutgers University. She was promoted to associate professor in 2005 and won the Board of Trustees Research Fellowship for Scholarly Excellence at Rutgers University. She moved to University of California, Riverside in 2005 as an associate professor and was promoted to full professor in 2009 and distinguished professor in 2013. In 2006, she received the prestigious Charles Albert Shull award from American Society of Plant Biologists. In 2011, she was elected an AAAS Fellow. She was an HHMI-GBMF investigator from 2012 to 2018. In 2013, she was elected into the US National Academy of Sciences. She received the Martin Gibbs Medal from American Society of Plant Biologists in 2023 and the Qiu Shi Outstanding Scientist Award from Qiu Shi Science & Technologies Foundations in 2024. In 2023, she returned to China to take up a full-time academic position and currently serves as Chair Professor and Dean of the School of Life Sciences at Peking University, as well as Director of Beijing Advanced Center for RNA Biology (BEACON). Her work has focused on flower development, small RNAs, and RNA modifications in plants.

Before joining the Chinese University of Hong Kong as Global Stem Scholar and Professor in the Faculty of Medicine, Stephen Dalton (SD) was Professor and Endowed Chair in Molecular Cell Biology at the University of Georgia where he was founding Director of the “Center for Molecular Medicine”, and Georgia Cancer Coalition Distinguished Scholar. Originally from the UK, Dr. Dalton received his Ph.D. from the University of Adelaide in Australia, followed by post-doctoral research at the Imperial Cancer Research Fund in London, with Sir Richard Treisman. Following this, SD was appointed to the Roche Institute of Molecular Biology (Hoffman La Roche, New Jersey, USA), with an academic appointment at Columbia University in New York City. Since then, SD has continued research on the therapeutic use of stem cells. This includes collaborations with Johnson and Johnson (New Jersey, USA), Nestle’ (Lausanne, Switzerland) and Viacyte Inc. (San Diego, USA), which was recently acquired by Vertex Pharmaceuticals. Dr. Dalton’s current work focusses on developing cell-therapy and gene-editing technologies for the treatment of human disease.

Professor Feng Yibin has been recognized as one of the top 1% highly cited researchers globally by Clarivate Analytics ESI for eight consecutive years since 2017. In 2024, he received the honor of “Global Highly Cited Researcher,” placing him in the top 0.1% worldwide. He has published over 630 papers. Additionally, Stanford University has listed him among the top 2% of scientists globally for 2022-2024. According to the 2024 AD Scientific Index, Professor Feng ranks 7th worldwide and 1st in Hong Kong in the field of Complementary and Integrative Medicine.

George Fu Gao has been a key leader in the public health field, making remarkable contributions to research and discovery through basic research, clinical evaluation and advocacy. He has made many remarkable contributions to the scientific field of control and prevention of emerging infectious diseases. He obtained his DPhil degree from Oxford University, UK and did his postdoc work in both Oxford University and Harvard University (with a brief stay in Calgary University). Gao worked in Beijing Agricultural University (1986-1991), Oxford University (2001-2006), Institute of Microbiology, Chinese Academy Sciences (2004-2008, Director-General). China CDC (Director-General, 2017-2022), National Science Foundation of China (Vice-President, 2018-2022). Gao is a member (academician) of Chinese Academy of Sciences (CAS), an international member of the U.S. National Academy of Sciences (NAS), a foreign member of the U.K. Royal Society (RS), a member of the German National Academy of Sciences Leopoldina, a fellow of African Academy of Sciences and a fellow of The World Academy of Sciences (TWAS).

G

Guo Jiguang, Ph.D., is an associate professor and master’s supervisor at the School of Basic Medical
Sciences, Hebei University. His main research areas include the pathogenesis of Parkinson’s disease
and therapeutic drugs. Received a bachelor’s degree in Biology from the University of Science and
Technology of China in 2001, a Doctor of Science degree from Shanghai Institutes for Life Sciences,
Chinese Academy of Sciences in 2009, and a visiting scholar at UCLA in 2016. He has presided over
one project funded by the National Natural Science Foundation of China and several provincial-level
projects, and participated in 973, 863 and several national-level projects. Published works such as
“Pathogenic Biology”, and published more than ten SCI papers in international journals such as Cell
Research, Genome Biology, and Peer J at home and abroad, and won the second prize of Science and
Technology Progress of Baoding City

Dr. I-Ming Hsing is Professor and Former Head of Chemical and Biological Engineering at the Hong Kong University of Science and Technology (HKUST). He holds a BSc from National Taiwan University (1990) and an MSCEP and PhD from MIT (1994, 1997). Dr. Hsing’s research integrates molecular biology, reaction engineering, and micro/nanofabrication to advance nucleic acid engineering and biomaterials. His group develops innovative diagnostics, including CRISPR-based platforms for point-of-care testing and community surveillance, and nature-derived biomaterials for chronic wound care. A pioneer in molecular diagnostics, he holds multiple patents and has published extensively. Dr. Hsing serves on the editorial boards of leading journals, serves as a member of the Hong Kong SAR Government’s Research Grants Council, and is the Founding President of the Asia Pacific Biomedical Engineering Consortium, fostering collaboration in biomedical engineering and translational medicine.

Dr. Kucherlapati is the Paul C. Cabot Professor of Genetics and Professor of Medicine at the Harvard Medical School since 2001. He was the founding Director of the Harvard Partners Center for Genetics and Genomics. He obtained his PhD from the University of illinois, conducted post-doctoral studies at Yale University and held faculty positions at Princeton University. Before moving to Harvard, Dr. Kucherlapati was the University Chairman and the Lola and Saul Kramer Professor and chair of the Department of Molecular Genetics at the Albert Einstein College of Medicine in New York. Dr. Kucherlapati was a part of the Human Genome Project and the Cancer Genome Atlas project. He is a member of the National Academy of Medicine, USA.

Prof. Chi-kong LI currently is Research Professor at Department of Paediatrics of The Chinese University of Hong Kong, and honorary consultant at Hong Kong Children’s Hospital. Dr. Li is specialized in paediatric haematology, oncology, stem cell transplantation and cellular therapy. He was the past Continental President of Asia of International Society of Pediatric
Oncology. His main interest is in childhood leukaemia, palliative care and bioethics. He has published over 400 peer-reviewed papers.